Starboard Focused on Kenvue's Struggling Unit
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
10 Analysts Have This To Say About Kenvue
In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...
Starboard says Kenvue's skin health segment weighing on performance
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster ...
Kenvue's Double Catalysts: Starboard Stake and Dividend Announcement
Kenvue has a formidable lineup of well-known consumer health brands, such as Aveeno, Tylenol, Band-Aid, Zirtec, Listerine, ...
BioSpace21h
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Starboard Says Kenvue's Skin Health Segment Is Weighing on Performance
NEW YORK (Reuters) - Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty ...